Biotech Startup Exsure Secures Major Investment for Global Expansion

Biotech startup Exsure has raised Rs 3 crore in a funding round led by Unicorn India Ventures to advance its exosomal drug-delivery platform for anti-cancer treatments. The funds will support Exsure's non-clinical studies and global expansion. The startup plans to finish studies and team building within 12 months.

In a significant funding round led by Unicorn India Ventures, biotech startup Exsure has successfully raised Rs 3 crore. Founded in 2021, the company aims to mitigate the side effects of anti-cancer drugs using its innovative exosomal drug-delivery platform targeting cancer cells and cancer stem cells.

This new financial injection will be pivotal in completing the necessary milestones for their non-clinical study using the exosome-based drug delivery system. Furthermore, the funds will bolster Exsure's ambition for global outreach and the promotion of its in-house developed products like Exsure, Leucosure, PlantExosure, and Dr Berries.

Exsure anticipates finalizing its non-clinical study, fortifying its team, and advancing its strategic objectives in the next 12 months, setting sights on becoming a leader in biotechnology innovations.

(With inputs from agencies.)